ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/Ganirelix
C80H113ClN18O13
1570.3 g/mol
APIDanger

Ganirelix

CAS123246-29-7
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

Ganirelix is a synthetic peptide compound that functions as a competitive gonadotropin-releasing hormone (GnRH) antagonist. It is used as an active pharmaceutical ingredient in assisted reproductive technology to suppress the pituitary production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Pharmaceutical raw material for controlled ovulation protocolsResearch compound in reproductive endocrinology studies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Ganirelix?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

StrongSame Parent

Ganirelix

CAS124904-93-4

pharmaceutical raw material

StrongSame Parent

Ganirelix acetate

CAS129311-55-3

pharmaceutical raw material

SimilarStructure SimilarSimilarity 0.84

Cetrorelix acetate

CAS130143-01-0

pharmaceutical raw material

SimilarStructure SimilarSimilarity 0.84

Cetrorelix

CAS120287-85-6

pharmaceutical raw material

ApplicationSame Use

Abarelix

CAS183552-38-7

pharmaceutical raw material

ApplicationSame Use

Iturelix

CAS112568-12-4

pharmaceutical raw material

ApplicationSame Use

Elagolix sodium

CAS832720-36-2

pharmaceutical raw material

ReferenceSame Category

Clofarabine

CAS123318-82-1

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more

Safety Reference

Health Hazard
Health Hazard
Danger
H360May damage fertility or the unborn child
H372Causes damage to organs through prolonged or repeated exposure
Identifiers
IUPAC Name

(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide

InChIKey

GJNXBNATEDXMAK-PFLSVRRQSA-N

SMILES

CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC

Synonyms (16)
  • Ganirelix (INN)
  • Ganirelixum [INN-Latin]
  • Antagon
  • Ganirelix
  • Ganirelixum
  • Orgalutran
  • Orgalutran (TN)

Sourcing Ganirelix?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→